| Market Cap | 3.98M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -11.65M | Forward P/E | 0.06 | EPS next Y | - | 50D Avg Chg | - |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -56.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -84.00% |
| Recommedations | 2.00 | Quick Ratio | 0.01 | Shares Outstanding | 61.76M | 52W Low Chg | 61.00% |
| Insider Own | 0.96% | ROA | -658.44% | Shares Float | 60.06M | Beta | 2.74 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.16 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 5,372 | Target Price | - |
| Oper. Margin | - | Earnings Date | Nov 13 | Volume | 1,150 | Change | 24.71% |
Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. Its lead product drug candidates include MYCO-005. The company also develops MYCO-006 and MYCO-007. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.